Global and Chinese Healthcare Simulators Market, By Product Type (Patients Simulators, Dental Simulators, Surgical Simulators, Ultrasound and Imagining Simulators, Others), By Service (Manikin-Based Simulation, Skills-Training Simulation, Tissue-based Simulation, Virtual Reality Simulation, Standardized Patient Simulation, and Others ), By Fidelity (Low fidelity, Medium fidelity, and High fidelity), By End User (Hospitals, Academic and Research Institutes, Military organization, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,913.9 million in 2021 and is expected to exhibit a CAGR of 14.9% during the forecast period (2021-2028).
Regulatory authorities has issued guidelines, rules and regulations for market players, which is expected to increase the growth of the global and Chinese healthcare simulators market over the forecast period. For instance, on August 29, 2018, the U.S. food and drug administration (FDA) issued guideline in the computational modeling and simulation (CM&S) states about elements and sections to be present in report of medical device application such as executive report summary, background, code verification, system configuration, governing equations/constitutive laws, system properties, system condition, system discretization, numerical implementation, validation and results explaining the technology or software.
Increasing inorganic activities such as collaborations, partnerships, and agreements among market players globally is expected to drive the growth of the global and Chinese healthcare simulator market over the forecast period. For instance, on November 4, 2021, GNS Healthcare, an artificial intelligence technological company, announced a collaboration with Scipher Medicine, a platform-based company that predicts the drug based on patients' fundamental biology. The aim behind this collaboration is to create and launch an insilico patient for rheumatoid arthritis, which will be designated as ‘Gemini insilico patient.’ It will link drug treatment in patients to complex genetics, pathways, and molecular mechanism for the simulation to check the drug response and disease progression in patients.
Global and Chinese Healthcare Simulators Market- Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic is expected to drive the growth of the global and Chinese healthcare simulators market over the forecast period. The COVID-19 is the recent pandemic outbreak which was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO), Weekly epidemiological update on COVID-19, the number of new cases and deaths continued to decrease, with nearly 262 million cases of COVID-19 were reported globally and with just under 5,224,519 deaths till November 30 , 2021.
Increasing funding opportunities by the government organizations for developments of laboratories, skill development and training centers is expected to increase the growth of the global and Chinese healthcare simulators market over the forecast period. For instance, on October 18, 2018, the Karnataka state government (India) granted funding of US$ 2,933,170 for setting modern simulation labs for neurosurgical simulators that will help students to practice critical surgeries such as brain and spine.
Browse 35 Market Data Tables and 45 Figures spread through 196 Pages and in-depth TOC on Global and Chinese Healthcare Simulators Market, By Product Type (Patients Simulators, Dental Simulators, Surgical Simulators, Ultrasound and Imagining Simulators, and Others), by Service (Manikin-Based Simulation, Skills-Training Simulation, Tissue-based Simulation, Virtual Reality Simulation, Standardized Patient Simulation, and Others), by Fidelity (Low fidelity, Medium fidelity, and High fidelity ), by End User (Hospitals, Academic and Research Institutes, Military organization, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the global and Chinese healthcare simulators market, click the link below:
Increasing funding opportunities by market players globally is expected to drive the growth of the global and Chinese healthcare simulators market over the forecast period. For instance, CAE Healthcare, a provider of simulation-based education, explained about grants available for funding opportunities in medical simulation market amid COVID pandemic. The CAE Healthcare will be providing a funding of US$ 2,000,000, which is the annual funding, which will be used for Nurse Education, Practice, Quality and Retention Simulation Education Training Program.
Key Takeaways of the Global and Chinese Healthcare Simulators Market:
- The global and Chinese healthcare simulators market is expected to exhibit a CAGR of 14.9% over the forecast period (2021-2028), owing to the growth in potential markets, especially in Europe. While North America region accounted for the major market share in year 2020.
- Market players are involved in presenting their research at the international conference for medical simulation, which is expected to drive the growth of global and Chinese healthcare simulators market. For instance, International Nursing Association for Clinical Simulation and Learning is planning to arrange conference from June 15 to June 18, 2022, at Wisconsin, U.S. for the market players in medical simulation. The objective of this conference is to provide platform to market players to present their new innovations in nursing simulation and examine the challenges in simulation and learning resource centers.
- Some of the major players operating in the global and Chinese simulators market include Laerdal Medical, 3M, 3D Systems, Simulab Corporation, Simulaids Inc., Kyoto Kagaku, Mentice , Medaphor, CAE Healthcare, Gaumard Scientific Company, Limbs & Things, BT INC., Trandomed 3D, Fujian Zhongli Co., Tellyes Scientific Co. Ltd., Kavo Dental , Surgical science AB, and Adam Rouilly Ltd.
